Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
06 Novembre 2018 - 10:30PM
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that
the Company will participate in the following investor conferences
in November and December:
- Credit Suisse’s 27th Annual Healthcare Conference on Tuesday,
November 13, 2018, at 2:50 p.m. Mountain Time in Scottsdale, AZ.
The Company will participate in a fireside chat at the conference,
which will be webcast live and available for replay from the
Investor Relations section of Portola’s website at
www.portola.com.
- Citi’s Global Healthcare Conference on Thursday, December 6,
2018, in New York, NY. The Company will conduct one-on-one meetings
with institutional investors at this conference.
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s two FDA-approved medicines are
Andexxa® [coagulation factor Xa (recombinant),
inactivated-zhzo], the first and only antidote for patients treated
with rivaroxaban and apixaban when reversal of anticoagulation is
needed due to life-threatening or uncontrolled bleeding, and
Bevyxxa® (betrixaban), the first and only oral, once-daily
Factor Xa inhibitor for the prevention of VTE in adult patients
hospitalized for an acute medical illness. The company also is
advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of
hematologic cancers.
Investor
Contact: |
Media
Contact: |
Cara Miller |
Patrick Ryan |
Portola
Pharmaceuticals |
Pure
Communications |
ir@portola.com |
pryan@purecommunications.com |
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur